Affinity DataIC50: 3.00E+3nMAssay Description:Tested for its ability to antagonize epinephrine induced primary wave aggregation in human platelets at alpha-2A-adrenergic receptor sites.More data for this Ligand-Target Pair
Affinity DataIC50: 3.40E+3nMAssay Description:Tested for its ability to antagonize epinephrine induced primary wave aggregation in human platelets at alpha-2A-adrenergic receptor sites.More data for this Ligand-Target Pair
Affinity DataIC50: 9.10E+3nMAssay Description:Tested for its ability to antagonize epinephrine induced primary wave aggregation in human platelets at alpha-2A-adrenergic receptor sites.More data for this Ligand-Target Pair
Affinity DataIC50: 1.23E+4nMAssay Description:Tested for its ability to antagonize epinephrine induced primary wave aggregation in human platelets at alpha-2A-adrenergic receptor sites.More data for this Ligand-Target Pair
Affinity DataIC50: 6.19E+4nMAssay Description:Tested for its ability to antagonize epinephrine induced primary wave aggregation in human platelets at alpha-2A-adrenergic receptor sites.More data for this Ligand-Target Pair
Affinity DataIC50: >3.00E+5nMAssay Description:Tested for its ability to antagonize epinephrine induced primary wave aggregation in human platelets at alpha-2A-adrenergic receptor sites.More data for this Ligand-Target Pair
Affinity DataIC50: 3.80E+5nMAssay Description:Tested for its ability to antagonize epinephrine induced primary wave aggregation in human platelets at alpha-2A-adrenergic receptor sites.More data for this Ligand-Target Pair
Affinity DataIC50: 5.80E+5nMAssay Description:Tested for its ability to antagonize epinephrine induced primary wave aggregation in human platelets at alpha-2A-adrenergic receptor sites.More data for this Ligand-Target Pair